Wet Age-Related Macular Degeneration (AMD) Market is expected to grow with the CAGR of 6.3% in the forecast period of 2020 to 2027. The years considered for study are as mentioned below.
Wet age-related macular degeneration (AMD) market is a highly consolidated market, which includes specific number of key players as well as local players. The market has witnessed increased strategic developments owing to favourable market scenario.
The major players dealing in wet age-related macular degeneration (AMD) market are introducing strong range of product portfolio. This helped companies to maximize the sales with enhanced product portfolio. For instance, in November, Coherus BioSciences entered into an agreement with Bioeq IP AG (now Bioeq AG or “Bioeq) for the commercialization of a biosimilar version of (Lucentis) ranibizumab in certain dosage forms in both a vial and pre-filled syringe presentation. This agreement benefitted Coherus BioSciences by providing the royalties to commercialize the Bioeq licensed products of ophthalmology segment in the U.S., thus increased sales and revenue in future.
F. Hoffmann-La Roche AG is the dominating player in Netherlands wet age-related macular degeneration (AMD) market. The other key players existing in the market includes Regeneron Pharmaceuticals, Inc., Allergan, Alcon Inc., Senju Pharmaceutical CO. Ltd., Outlook Therapeutics, Inc., Coherus Biosciences, Pfizer Inc., Boehringer Ingelheim International GMBH, Bausch Health, Novartis AG, Bayer AG and Santen Pharmaceuticals Co., Ltd,.
F. Hoffmann-La Roche Ltd
F. Hoffmann-La Roche Ltd, headquartered in Basel, Switzerland which was founded in 1896. The company is engaged in manufacturing of various pharmaceuticals, solutions for diagnostics and products for researchers products and their business segments are pharmaceuticals and diagnostics out of which market focused segment is pharmaceuticals.
The company has wide global presence across the globe such as Europe, North America, Asia-Pacific, Africa, Oceania. In addition to it, the company also generates its revenue from the various subsidiary companies such as Genentech, Inc.(U.S.), Roche Diagnostics Limited (U.K),Chugai Pharmaceutical Co (Japan), Flatiron Health, Inc. (U.S.), Ventana Medical Systems (U.S.), Kapa Biosystems, Inc. (U.S.), among others
REGENERON PHARMACEUTICALS, INC.
REGENERON PHARMACEUTICALS, INC.is headquartered in New York, U.S. and it was founded in year 1988. The company focuses on inventing life-transforming medicines for people with serious diseases.
The company has presence in U.S., The Netherlands and Ireland with its various subsidiaries such as Loop Road Holdings LLC (U.S.), Old Saw Mill Holdings LLC (U.S.), OSMR LLC (U.S.), Regeneron Capital International B.V. (The Netherlands) and Regeneron International Limited (Ireland) among others.
Bausch Health is headquartered in Quebec, Canada. The company's primary focus is in the areas of ophthalmic specially contact lenses, intraocular lenses, ophthalmic surgical equipment and aesthetic devices. The company has business segments which are pharmaceuticals, over-the-counter (OTC) products, medical devices, branded and other generics and others, among which pharmaceuticals is market focused segment. The company offers its products in different categories such as dermatology, gastrointestinal, eye health, consumer health, dentistry, generics, neurology and other. In which the market focused category is eye health and consumer health.
The company has wide global presence in North America, South America, Asia-Pacific, Europe and Middle East & Africa.